Olema Oncology
United States
86 articles about Olema Oncology
-
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 03, 2023
10/3/2023
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, announced that the Company granted stock options to one new employee to purchase an aggregate of 30,000 shares of the Company's common stock, effective as of October 2, 2023.
-
Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9/20/2023
Olema Pharmaceuticals, Inc. ( “Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced a poster presentation on new discovery compounds targeting KAT6, an epigenetic target that is dysregulated in breast and other cancers.
-
Olema Oncology to Participate in Upcoming September 2023 Investor Conferences
9/6/2023
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, announced that the Company will present at the following upcoming investor conferences in September.
-
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 05, 2023
9/5/2023
Olema Pharmaceuticals, Inc. announced that the Company granted stock options to one new employee to purchase an aggregate of 61,000 shares of the Company's common stock, effective as of September 1, 2023.
-
Olema Oncology Announces Combined Financing for Up to $180 Million
9/5/2023
Olema announced today that it has entered into a stock purchase agreement for a private placement of approximately $130 million of common stock.
-
Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8/8/2023
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.
-
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 02, 2023
8/2/2023
Olema Pharmaceuticals, Inc. announced that the Company granted stock options to two new employees to purchase an aggregate of 29,100 shares of the Company's common stock, effective as of August 1, 2023.
-
Olema Oncology to Present at the Canaccord Genuity 43rd Annual Growth Conference
8/1/2023
Olema Pharmaceuticals, Inc. announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference in Boston on Wednesday, August 9, 2023, at 2:00 p.m. ET.
-
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
7/5/2023
Olema Pharmaceuticals, Inc. today announced that the Company granted stock options to three new employees to purchase an aggregate of 32,300 shares of the Company's common stock, effective as of July 3, 2023.
-
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 02, 2023
6/2/2023
Olema Pharmaceuticals, Inc. announced that the Company granted stock options to two new employees to purchase an aggregate of 17,400 shares of the Company's common stock, effective as of June 1, 2023.
-
Olema Oncology to Present at the 2023 Jefferies Healthcare Conference
5/30/2023
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA) today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a Fireside Chat at the 2023 Jefferies Healthcare Conference in New York on Wednesday, June 7, 2023, at 3:00 p.m. ET.
-
Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study
5/11/2023
Olema Pharmaceuticals, Inc. today announced interim results from an ongoing Phase 1b/2 clinical study of OP-1250, the Company’s complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD), in combination with palbociclib, a CDK4/6 inhibitor, for the treatment of ER+/HER2- metastatic breast cancer.
-
Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update
5/9/2023
Olema Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.
-
Olema Oncology Announces Upcoming Poster Presentation at the 2023 ESMO Breast Cancer Annual Congress
5/8/2023
Olema Pharmaceuticals, Inc. today announced a poster presentation on OP-1250, the Company’s complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in development for the treatment of metastatic breast cancer, at the upcoming ESMO Breast Cancer Annual Congress 2023 taking place May 11-13, 2023, in Berlin, Germany.
-
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 02, 2023
5/2/2023
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, announced that the Company granted stock options to two new employees to purchase an aggregate of 23,100 shares of the Company's common stock, effective as of May 1, 2023.
-
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 04, 2023
4/4/2023
Olema Pharmaceuticals, Inc. announced that the Company granted stock options to two new employees to purchase an aggregate of 11,800 shares of the Company's common stock, effective as of April 3, 2023.
-
Olema Oncology Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Strategic Update
3/9/2023
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today reported financial results for the fourth quarter and full-year ended December 31, 2022, and provided a strategic update.
-
Olema Oncology to Present at Oppenheimer 33rd Annual Healthcare Conference
3/2/2023
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that Sean Bohen, M.D., Ph.D., President and Chief Executive Officer, will present at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15, 2023, at 2:40 p.m. ET.
-
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 02, 2023
3/2/2023
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, announced that the Company granted stock options to three new employees to purchase an aggregate of 42,300 shares of the Company's common stock, effective as of March 1, 2023.
-
Olema Oncology to Participate at Upcoming Investor Conferences - February 21, 2023
2/21/2023
Olema Pharmaceuticals, Inc. announced that the Company will present at the following upcoming investor conferences: